Donanemab and Lecanemab rejected for the NHS

Two innovative Alzheimer’s drugs, donanemab and lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending independent living, by clearing a protein build up in the brain. However, they neither reverse nor halt Alzheimer’s, only slowing cognitive decline. The...